

NEWS RELEASE**Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy**

Tokyo, Japan, April 10, 2024 --- [Teijin Pharma Limited](#), the core company of the [Teijin Group](#)'s healthcare business, announced today that it has entered into an exclusive global licensing agreement with Bioprojet, a French pharmaceutical company. Under the terms of the agreement, Teijin Pharma grants Bioprojet exclusive worldwide rights to research, develop, manufacture and commercialize an investigational candidate for narcolepsy.

The investigational candidate is a highly potent and selective orexin 2 receptor agonist discovered at the Teijin Institute for Bio-medical Research in Tokyo. The candidate is expected to compensate for a deficiency in orexins, brain peptides that help sustain alertness and prevent rapid eye movement (REM) sleep from occurring at the wrong times. The mechanism of action (MoA) of this class of compounds has been demonstrated and could represent the next novel MoA for the treatment of narcolepsy and other sleep/wake disorders.

Narcolepsy is a sleep disorder that is characterized by excessive daytime sleepiness and cataplexy (episodic loss of muscle tone triggered by emotions). Its prevalence is estimated to be around 25 to 50 cases per 100,000 people. Current approved therapies objectives are to promote wakefulness and decrease cataplexy attacks.

Bioprojet, founded in 1982, researches, develops and sells pharmaceuticals in areas such as neurology, immunology, allergies and rare diseases. The company's leading product is pitolisant (brand name: Wakix[®]), a histamine H3 receptor antagonist/inverse agonist that is already widely marketed for the treatment of both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

According to the terms of the agreement, Teijin Pharma will receive an upfront payment of \$30 million USD from Bioprojet. In addition, it is eligible to receive approximately \$400 million USD in total milestone revenue according to the progress of development and the achievement of sales targets, as well as tiered annual net sales royalties.

Teijin Pharma has made this agreement to contribute to improving the quality of life (QOL) for narcolepsy patients around the world by licensing this compound to Bioprojet, which has a proven track record in developing and commercializing pitolisant for the treatment of narcolepsy.

Teijin Group's healthcare business has been transforming its business model to support patients

with rare diseases based on the infrastructure in home healthcare business. In the discovery section of pharmaceutical business, through licensing or external partnerships, Teijin will continue making a social contribution by delivering innovative treatments to patients around the world.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Through "Human Chemistry, Human Solutions," Teijin relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities. Teijin posted consolidated sales of JPY 1,018.8 billion (USD 7.6 billion) and total assets of JPY 1,242.4 billion (USD 9.2 billion) in the fiscal year ending March 31, 2023.

Please visit www.teijin.com

Press Contact

Investor and Public Relations Department

Teijin Limited

+81 (0)3 3506 4055

pr@teijin.co.jp